"Each client is unique and requires an individual approach. Guided by this philosophy, our specialists develop intelligent and 100% efficient multidisciplinary programs in preclinical drug research and safety evaluation"

Serge Richard (CEO)





QT shift and probabilistic method: powerful approaches for detection of QT prolongation in a most reliable manner.

Le contenu de cette page nécessite une version plus récente d’Adobe Flash Player.

Obtenir le lecteur Adobe Flash



TDPscreen: in silico modeling for prediction of torsadogenic profiles

Le contenu de cette page nécessite une version plus récente d’Adobe Flash Player.

Obtenir le lecteur Adobe Flash


Founded in 1973, CERB has developed to a leading international contract research organization (CRO) in the fields of preclinical pharmacology and toxicology. Taking on the challenges of modern drug development CERB has created its distinctive image of a major service provider to the pharmaceutical industry in the context of innovative biomedical research.

Our toxicology department has also proven to be a valuable partner to other branches, such as chemical and agro-chemical industries, in the field of regulatory safety assessment.


For the pharmaceutical industry, CERB takes advantage of its sophisticated synergy between pharmacology and toxicology resources to provide complete pre-phase I packages for a new molecule in an economic and timely manner. Having developed/validated more than 200 models and techniques in pharmacology and toxicology we take on any challenge of specialized approaches fitting the requirements of your compound. A fully equipped chemical analysis unit assures back-up support for drug quantification in chemical or biological matrices as well as biomarker verification.

Our main assets are:


  • high quality of scientific and administrative performance
  • continuous innovation through targeted scientific input
  • a network of independent, internationally renowned experts and cooperations
  • the dedication to provide custom-made answers
  • reactivity and flexibility


Last publications:

2018 Behav brain Res "Relevance of electroencephalogram assessment in amyloid and tau pathology in rat"

2018 Br J Pharmacol "High-frequency autonomic modulation: a new model for analysis of autonomic cardiac control"

2016 Br J Pharmacol "The high frequency relationship: implications for torsadogenic hERG blockers"

2015 Br J Pharmacol "Short term variability in QT interval and ventricular arrhythmias are dependent on high frequency autonomic oscillations"

2014 J Pharmacol Toxicol Methods "Preclinical QT safety assessment: Cross-species comparisons and human translation from an industry consortium"

2013 J Pharmacol Methods "Power spectral analysis of heart rate variability in cynomolgus monkeys in safety pharmacology studies: Comparative study with beagle dogs"